AUS Edition 
NZ Edition 
UK Edition 
CA Edition 
USA Edition 
IND Edition 
⚠
✓
Sponsored Reports
Loading...
| Previous Close (in USD) | 2.41 |
|---|---|
| Change | -0.010 0.415% |
| 52 W H/L (in USD) | 3.870/0.958 |
| EBITDA (in USD) | -33.084M |
| PE Ratio | -- |
| Volume | 350649 |
| Diluted Eps TTM | -0.50 |
| Total Assets (in USD) | 147.797M |
|---|---|
| Total Liabilities (in USD) | 97.268M |
| Revenue TTM (in USD) | 70.387M |
| Cash (in USD) | 50.793M |
| Market Cap (in USD) | 218.995 M |
| Revenue Per Share TTM | 0.808 |
| Gross Profit TTM (in USD) | 8.742M |
Summary
Income Statement
Balance Sheet
Change in Cash
Operating Cash
Codexis Inc
Codexis, Inc. provides technology solutions for therapeutics manufacturing, leveraging its proprietary CodeEvolver technology platform to discover, develop, enhance, and commercialize novel enzymes in the United States, Canada, Latin America, Europe, the Middle East, Africa, Australia, New Zealand, Southeast Asia, and China. The company develops its proprietary ECO Synthesis manufacturing platform to enable the scaled manufacture of RNAi therapeutics through an enzymatic route. It has a license agreement with Aldevron LLC and Pfizer Inc. The company was incorporated in 2002 and is headquartered in Redwood City, California.
Employees: 146
Key Executives
| Sr. No. | Name | Title | Year Born |
|---|---|---|---|
| 1. | Dr. Stephen George Dilly MBBS, Ph.D. | Pres, CEO & Director | 1960 |
| 2. | Mr. Ross Taylor Jr., M.B.A. | Sr. VP & CFO | 1963 |
| 3. | Mr. John J. Nicols | Director & Strategic Advisor | 1964 |
| 4. | Mr. Kevin Norrett M.B.A., M.S. | Chief Operating Officer | 1973 |
| 5. | Ms. Margaret Fitzgerald J.D. | Chief Legal and Compliance Officer, Gen. Counsel & Sec. | NA |
| 6. | Ms. Asli Aras Ph.D. | VP & Head of Corp. Devel. | NA |
| 7. | Ms. Karen Frechou-Armijo | Sr. VP & Head of HR | NA |
| 8. | Mr. Rob Wilson Ph.D. | Sr. VP & GM of Performance Enzymes | NA |
| 9. | Dr. Karl A. Schoene Ph.D. | Sr. VP of Devel. & Operations | NA |
| 10. | Dr. Stefan Lutz Ph.D. | Sr. VP of Research | NA |
Peers
Sector: Healthcare
Industry: Biotechnology
| Company | Change (USD) | Price (USD) | Trailing PE(x) | Forward PE(x) | Price Sales TTM(x) | Price to Book Value(x) | Enterprise Value to Revenue(x) | Enterprise Value to EBITDA(x) |
|
NVO
Novo Nordisk A/S |
-0.080 0.182% | 43.94 | 41.580 | 31.153 | 2.134 | 32.989 | 2.113 | 4.700 |
|
NONOF
Novo Nordisk A/S |
+1.990 4.737% | 44 | 41.060 | 31.250 | 2.078 | 33.111 | 2.113 | 4.700 |
|
VRTX
Vertex Pharmaceuticals Inc |
-0.115 0.026% | 440.02 | 29.670 | 24.331 | 10.385 | 5.832 | 9.334 | 20.004 |
|
REGN
Regeneron Pharmaceuticals Inc |
+0.660 0.108% | 613.11 | 29.070 | 20.121 | 7.570 | 3.823 | 6.950 | 19.423 |
Income Statement
(Currency in USD)| Breakdown | 31-12-2025 | 31-12-2024 | 31-12-2023 | 31-12-2022 | 31-12-2021 |
|---|---|---|---|---|---|
| Income Before Tax | -43.927M | -65.242M | -76.171M | -33.316M | -21.09M |
| Minority Interest | - | - | - | - | - |
| Net Income | -43.974M | -65.276M | -76.24M | -33.592M | -21.279M |
| Selling General Administrative | 47.074M | 55.148M | 52.95M | 52.172M | 49.323M |
| Gross Profit | 55.952M | 43.057M | 57.334M | 100.557M | 82.545M |
| Reconciled Depreciation | 5.248M | 4.946M | 10.621M | 10.251M | 5.947M |
| Ebit | -38.332M | -58.354M | -54.801M | -31.714M | -28.644M |
| Ebitda | -30.04M | -58.519M | -49.283M | -28.547M | -22.697M |
| Depreciation And Amortization | 8.292M | -0.165M | 5.518M | 3.167M | 5.947M |
| Operating Income | -38.332M | -58.519M | -68.069M | -31.714M | -22.697M |
| Other Operating Expenses | 108.719M | 117.864M | 138.212M | 170.304M | 127.451M |
| Interest Expense | 4.813M | 10.393M | 12.274M | 1.441M | 7.554M |
| Tax Provision | 0.047M | 0.034M | 0.185M | 0.276M | 0.189M |
| Interest Income | 2.625M | 3.67M | 4.089M | 1.441M | 0.459M |
| Net Interest Income | -2.188M | 3.67M | 4.089M | 1.441M | 0.459M |
| Income Tax Expense | 0.047M | 0.034M | 0.069M | 0.276M | 0.189M |
| Total Revenue | 70.387M | 59.345M | 70.143M | 138.59M | 104.754M |
| Total Operating Expenses | 94.284M | 101.576M | 125.403M | 132.271M | 105.242M |
| Cost Of Revenue | 14.435M | 16.288M | 12.809M | 38.033M | 22.209M |
| Total Other Income Expense Net | -5.595M | -6.723M | -8.102M | -1.602M | 1.607M |
| Net Income From Continuing Ops | -43.974M | -65.276M | -81.652M | -33.592M | -21.279M |
| Net Income Applicable To Common Shares | - | - | - | -33.592M | -21.279M |
Balance Sheet
(Currency in USD)| Breakdown | 31-12-2025 | 31-12-2024 | 31-12-2023 | 31-12-2022 | 31-12-2021 |
|---|---|---|---|---|---|
| Total Assets | 147.797M | 149.011M | 136.561M | 250.393M | 246.383M |
| Intangible Assets | - | - | - | - | - |
| Other Current Assets | 6.061M | 4.631M | 5.218M | 5.487M | 6.279M |
| Total Liab | 97.268M | 82.084M | 49.946M | 105.596M | 81.992M |
| Total Stockholder Equity | 50.529M | 66.927M | 86.615M | 144.797M | 164.391M |
| Other Current Liab | 13.81M | 17.633M | 15.981M | 26.732M | 23.697M |
| Common Stock | 0.009M | 0.008M | 0.007M | 0.006M | 0.006M |
| Capital Stock | 0.009M | 0.008M | 0.007M | 0.006M | 0.006M |
| Retained Earnings | -606.78M | -562.806M | -497.53M | -421.29M | -387.698M |
| Good Will | 2.463M | 2.463M | 2.463M | 3.241M | 3.241M |
| Other Assets | - | - | - | 1.871M | 1.795M |
| Cash | 50.793M | 19.264M | 65.635M | 113.984M | 116.797M |
| Cash And Equivalents | - | - | - | - | - |
| Total Current Liabilities | 25.317M | 23.648M | 35.83M | 49.066M | 33.371M |
| Current Deferred Revenue | 7.009M | 0.35M | 3.781M | 13.728M | 2.586M |
| Net Debt | 22.415M | 40.631M | -43.271M | -70.346M | -69.143M |
| Short Term Debt | 2.944M | 2.827M | 10.121M | 5.36M | 4.093M |
| Short Long Term Debt | - | - | - | - | - |
| Short Long Term Debt Total | 73.208M | 59.895M | 22.364M | 43.638M | 47.654M |
| Other Stockholder Equity | 657.292M | 629.673M | 584.138M | 566.081M | 552.083M |
| Property Plant Equipment | - | - | - | 61.877M | 65.457M |
| Total Current Assets | 96.816M | 98.772M | 93.466M | 162.894M | 161.888M |
| Long Term Investments | 2.498M | 2.798M | 9.7M | 20.51M | 14.002M |
| Short Term Investments | 27.416M | 54.194M | - | - | 0M |
| Net Receivables | 10.729M | 18.884M | 19.928M | 40.873M | 37.652M |
| Long Term Debt | 40.105M | 28.905M | - | - | - |
| Inventory | 1.817M | 1.799M | 2.685M | 2.029M | 1.16M |
| Accounts Payable | 1.554M | 2.838M | 5.947M | 3.246M | 2.995M |
| Accumulated Other Comprehensive Income | 0.008M | 0.052M | 0M | - | - |
| Non Currrent Assets Other | 2.495M | 2.081M | 1.246M | 1.871M | 1.795M |
| Non Current Assets Total | 50.981M | 50.239M | 43.095M | 87.499M | 84.495M |
| Capital Lease Obligations | 33.103M | 30.99M | 16.024M | 43.638M | 47.654M |
| Long Term Debt Total | - | - | - | - | - |
Cash Flow
(Currency in USD)| Breakdown | 31-12-2025 | 31-12-2024 | 31-12-2023 | 31-12-2022 | 31-12-2021 |
|---|---|---|---|---|---|
| Investments | 27.968M | -56.98M | -5.929M | -13.578M | -7.63M |
| Total Cashflows From Investing Activities | 23.502M | -56.98M | -4.858M | -13.578M | -21.422M |
| Total Cash From Financing Activities | 27.928M | 60.522M | 8.167M | -0.575M | 3.767M |
| Net Income | -43.974M | -65.276M | -76.24M | -33.592M | -21.279M |
| Change In Cash | 32.054M | -45.868M | -49.329M | -2.869M | -31.922M |
| Begin Period Cash Flow | 20.829M | 66.697M | 116.026M | 118.895M | 150.817M |
| End Period Cash Flow | 52.883M | 20.829M | 66.697M | 116.026M | 118.895M |
| Total Cash From Operating Activities | -19.376M | -49.41M | -52.638M | 11.284M | -14.267M |
| Depreciation | 5.248M | 4.946M | 9.923M | 10.251M | 5.947M |
| Other Cashflows From Investing Activities | 0.005M | 0.087M | -0.44M | - | 0.036M |
| Dividends Paid | - | - | - | - | - |
| Change To Inventory | -0.019M | 0.886M | -0.656M | -0.869M | -0.196M |
| Sale Purchase Of Stock | - | - | -0.404M | - | 4.973M |
| Other Cashflows From Financing Activities | 27.928M | -0.318M | -0.485M | -1.53M | 3.767M |
| Capital Expenditures | 4.471M | 4.305M | 4.418M | 8.307M | 13.828M |
| Change In Working Capital | 6.418M | -12.016M | -18.217M | 21.572M | -7.624M |
| Other Non Cash Items | 3.308M | 9.849M | 21.925M | -1.478M | -0.019M |
| Free Cash Flow | -23.847M | -53.715M | -57.056M | 2.977M | -28.095M |
Funds
| Sr. No. | Name | Purchased On | Shares |
|---|---|---|---|
| 1. | abrdn Healthcare Investors | 3 months ago | 5232466 |
| 2. | abrdn Life Sciences Investors | 2 months ago | 3090272 |
| 3. | Vanguard Total Stock Mkt Idx Inv | 2 months ago | 2633770 |
| 4. | Columbia Small Cap Value Discv A | 2 months ago | 2500490 |
| 5. | Columbia Small Cap Value Discovery Fund | 5 months ago | 2387990 |
| 6. | iShares Russell 2000 ETF | 2 months ago | 2202102 |
| 7. | Vanguard Institutional Extnd Mkt Idx Tr | 2 months ago | 880901 |
| 8. | Fidelity Small Cap Index | 4 months ago | 842068 |
| 9. | iShares Biotechnology ETF | 2 months ago | 684837 |
| 10. | iShares Russell 2000 Growth ETF | 2 months ago | 590440 |
| 11. | Russell 2000 Equity Index Fund B | 5 months ago | 547959 |
| 12. | Putnam U.S. Small Cap Value Equity | 5 months ago | 529200 |
| 13. | Putnam Small Cap Value Managed Account | 5 months ago | 529200 |
| 14. | Columbia VP Small Cap Value 1 | 2 months ago | 498560 |
| 15. | Putnam Small Cap Value A | 2 months ago | 492703 |
| 16. | State St Russell Sm/Mid Cp® Indx SL Cl I | 2 months ago | 442118 |
| 17. | Vanguard Russell 2000 ETF | 2 months ago | 439828 |
| 18. | Fidelity Extended Market Index | 3 months ago | 419189 |
| 19. | Lazard US Small Cap Equity WW Dist EUR | 5 months ago | 407886 |
| 20. | Extended Equity Market Fund B | 5 months ago | 258245 |
Institutions
| Sr. No. | Name | Purchased On | Shares |
|---|---|---|---|
| 1. | Aberdeen Group PLC | 5 months ago | 7966498 |
| 2. | BlackRock Inc | 8 months ago | 7143948 |
| 3. | Opaleye Management Inc | 5 months ago | 6789738 |
| 4. | Vanguard Group Inc | 5 months ago | 4941542 |
| 5. | Nantahala Capital Management, LLC | 5 months ago | 3990169 |
| 6. | Telemark Asset Management, LLC | 5 months ago | 3846411 |
| 7. | Millennium Management LLC | 5 months ago | 3135192 |
| 8. | Ameriprise Financial Inc | 8 months ago | 2773646 |
| 9. | Prescott Group Capital Management LLC | 5 months ago | 2568359 |
| 10. | Geode Capital Management, LLC | 5 months ago | 2026006 |
| 11. | State Street Corp | 8 months ago | 1540754 |
| 12. | Jacobs Levy Equity Management, Inc. | 5 months ago | 1135190 |
| 13. | Franklin Resources Inc | 8 months ago | 756158 |
| 14. | Renaissance Technologies Corp | 5 months ago | 737485 |
| 15. | The Goldman Sachs Group Inc | 5 months ago | 718109 |
| 16. | Private Advisor Group, LLC | 5 months ago | 654581 |
| 17. | Northern Trust Corp | 8 months ago | 645274 |
| 18. | FMR Inc | 5 months ago | 641926 |
| 19. | D. E. Shaw & Co LP | 5 months ago | 628291 |
| 20. | Post Resch Tallon Group Inc. | 2 months ago | 571478 |
Data Powered by EOD Historical Data (“EODHD”). All CFDs (stocks, indices, mutual funds, ETFs), and Forex are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. EODHD is not using exchanges data feeds for the pricing data, EODHD is using OTC, peer to peertrades and trading platforms over 100+ sources, EODHD is aggregating its data feeds via VWAP method. Therefore, EOD Historical Data doesn’t bear any responsibility for any trading losses you might incur as a result of using this data. EOD Historical Data or anyone involved with EOD Historical Data will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. EOD Historical Data does not give any warranties (including, without limitation, as to merchantability or fitness for a particular purpose or use).
Sponsored Articles
Loading...
Related Articles
Loading...